Boosters in Development

See also: HIV Drugs in Development

Studies on Pipeline ARVs: Quad, Evitegravir/Cobicistat, Cobicistat, GSK1265744, BMS986001 Dolutegravir, GSK-1265744, Long-Acting Formulations (Monthly Injections): Rilpivirine-LA, Raltegravir and Patient Views (May/June 2012)
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
An Overview of Cobicistat (GS-9350) (October 25, 2010)
From AIDSinfo
"Quad" Pill Continues to Impress in Week-48 Results; Cobicistat Moves Forward in Battle With Ritonavir (September 14, 2010)
In The 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
"Quad" Tablet vs. Atripla; GS 9350 (Cobicistat) vs. Ritonavir (March 8, 2010)
Part of a CROI 2010 wrap-up discussion with Joel Gallant, M.D., M.P.H.
In The 17th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Good Results for New Booster and Quad Pill (Winter/Spring 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Elvitegravir "Quad" Pill Performs Well, New Booster Cobicistat Works as Well as Ritonavir (February 18, 2010)
From aidsmap.com
The New Quad on the Block: Gilead's Four-Drug, Fixed-Dose Combination With a Novel Booster Sails Through Phase 2 Trials (Feb. 18, 2010; 1:15 a.m. Pacific Time)
A blog entry from CROI 2010 by Myles Helfand.
In The 17th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
New Boosting Drug Looks Promising (February 2010)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
GS-9350, a "Norvir Alternative," Shows Promise in New Study (September 21, 2009)
From aidsmap.com
The Next Generation of Boosters: Promising Data on Potential Alternatives to Ritonavir (February 9, 2009)
Brian Kearney, Pharm.D., of Gilead Sciences Inc., and Robert Guttendorf, Ph.D., of Sequoia Pharmaceuticals discuss encouraging findings from early human trials on a pair of pharmacokinetic enhancers whose utility could potentially extend far beyond protease inhibitor boosting.
In The 16th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com

More Most Viewed Articles

HIV Tools You Can Use

Track Your CD4 Count, Viral Load and More: Use TheBody.com's Health Tracker

TheBody.com's Medication and Health Reminders
TheBody.com's Facebook, Widgets, RSS Feeds and Twitter
Are You at Risk for HIV? Take Our Quiz!
U.S. ASO Finder U.S. ASO Listings
International ASOs

The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.